StockNews.com initiated coverage on shares of InVivo Therapeutics (NASDAQ:NVIV – Get Rating) in a research report issued on Saturday. The brokerage set a “sell” rating on the biotechnology company’s stock.
Shares of NVIV opened at $4.54 on Friday. InVivo Therapeutics has a fifty-two week low of $3.50 and a fifty-two week high of $23.19. The business’s 50-day moving average is $6.68 and its two-hundred day moving average is $9.91.
Several institutional investors have recently made changes to their positions in NVIV. Renaissance Technologies LLC increased its stake in shares of InVivo Therapeutics by 152.5% in the 1st quarter. Renaissance Technologies LLC now owns 79,300 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 47,900 shares in the last quarter. Goldman Sachs Group Inc. acquired a new position in shares of InVivo Therapeutics during the 2nd quarter worth approximately $30,000. Two Sigma Securities LLC acquired a new position in shares of InVivo Therapeutics during the 3rd quarter worth approximately $31,000. Morgan Stanley boosted its holdings in shares of InVivo Therapeutics by 1,525.9% during the 2nd quarter. Morgan Stanley now owns 50,697 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 47,579 shares during the last quarter. Finally, Virtu Financial LLC acquired a new position in shares of InVivo Therapeutics during the 4th quarter worth approximately $58,000. Hedge funds and other institutional investors own 18.64% of the company’s stock.
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI.
- Get a free copy of the StockNews.com research report on InVivo Therapeutics (NVIV)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Will John Deere’s Earnings Help to Calm the Markets?
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Lowe’s Companies Has Not Bottomed
Receive News & Ratings for InVivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVivo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.